Keith Michael Sullivan, MD

Professor of Medicine
James B. Wyngaarden Professor of Medicine, in the School of Medicine
Member of the Duke Cancer Institute
Campus mail Box 3961 Med Ctr, Durham, NC 27710
Phone (919) 668-1000
Email address

Research areas

  • Late effects of cancer treatment and stem cell transplantation 
  • Chronic graft-versus-host disease 
  • Transplantation for sickle cell and autoimmune diseases 
  • Knowledge engineering

Early on, Dr. Sullivan and the team at Fred Hutchinson Cancer Research Center developed a systematic investigative approach for the diagnosis and treatment of chronic graft-versus-host disease (GVHD), the major cause of late morbidity and non-relapse mortality following allogeneic stem cell transplantation (SCT). As a result of this work, it became clear that blood and marrow transplant recipients require systematic long-term follow-up to evaluate and treat late complications of high-dose chemoradiotherapy and SCT.

The program grew into a large multidisciplinary team, resulting in improvement in patient outcome and quality of life. Through the late events project, he also contributed to outcomes research, computer decision support systems, and knowledge engineering for follow-up care. With quality of life as a focus, research pursued the application of SCT to diseases with high morbidity but little immediate mortality. For young patients with advanced, symptomatic sickle cell disease, myeloablative conditioning and SCT from an HLA-identical sibling has led to an 86% long-term survival free of sickle cell disease. For individuals with autoimmune diseases such as multiple sclerosis, scleroderma, and systemic lupus erythematosus, current therapy is often incomplete and significant morbidity from the disease or its treatment is observed.

Recent preclinical and clinical data suggest that high-dose immunosupression and SCT can halt the progression and, in some settings, reverse the course of autoimmune diseases. Since his arrival at Duke University, over 30 centers nationwide are participating in Duke-led phase II and III trials to test the toxicity, efficacy, and quality of life following autologous and allogeneic stem cell transplantation for autoimmune diseases.

These trials will also serve as platforms to study the immune repertoire and mechanistic pathways before and after SCT to gain greater insight into the basic mechanisms of autoimmunity.

A national repository of tissue and cell specimens is also part of these NIH-supported trials to further promote scientific study from these unique patients.

In Their Words

Education and Training

  • M.D., Indiana University at Indianapolis, 1971


Sullivan, Keith M., Peter A. McSweeney, and Richard A. Nash. “Cyclophosphamide in scleroderma lung disease..” N Engl J Med 355, no. 11 (September 14, 2006): 1173–74.


Nash, Richard A., Peter A. McSweeney, Leslie J. Crofford, Kevin T. McDonagh, Keith M. Sullivan, Mayes Maureen, J Lee Nelson, et al. “5-year follow-up of high-dose immunosuppressive therapy (HDIT) for systemic sclerosis (SSc)..” In Arthritis and Rheumatism, 54:S315–S315. WILEY-LISS, 2006.


Nash, Richard A., Peter A. McSweeney, J Lee Nelson, Mark Wener, George E. Georges, Amelia A. Langston, Howard Shulman, et al. “Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis..” Arthritis Rheum 54, no. 6 (June 2006): 1982–86.

Full Text

Rizzieri, D. A., L. P. Koh, G. D. Long, C. Gasparetto, K. M. Sullivan, M. Horwitz, J. Chute, et al. “Partially HLA matched, non-myeloablative allogeneic transplantation.” In Blood, 106:812A-812A. AMER SOC HEMATOLOGY, 2005.


Rizzieri, D. A., L. P. Koh, G. D. Long, C. Gasparetto, J. Z. Gong, A. S. Lagoo, D. Niedzwiecki, et al. “Outcome and immune reconstitution following T cell depleted nonmyeloablative allogeneic transplantation using matched donors.” In Blood, 106:576A-576A. AMER SOC HEMATOLOGY, 2005.


Griffith, Linda M., Steven Z. Pavletic, Alan Tyndall, Christopher N. Bredeson, James D. Bowen, Richard W. Childs, Alois Gratwohl, et al. “Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005..” Biol Blood Marrow Transplant 11, no. 11 (November 2005): 862–70.

Full Text

Storek, Jan, Zhao Zhao, Eugene Lin, Thomas Berger, Peter A. McSweeney, Richard A. Nash, Yoshiki Akatsuka, et al. “Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)..” Clin Immunol 113, no. 3 (December 2004): 285–98.

Full Text

Furst, Daniel E., Richard Nash, Keith M. Sullivan, Riccardo Saccardi, and Peter McSweeney. “High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward..” J Rheumatol 31, no. 12 (December 2004): 2331–35.


Walters, M. C., M. Patience, S. Edwards, S. Robertson, M. McMurray, S. Donfield, and K. M. Sullivan. “Hematopoietic cell transplantation for sickle cell disease: Updated results of the multicenter trial..” In Blood, 104:33A-33A. AMER SOC HEMATOLOGY, 2004.